Novo Nordisk A/S (NYSE:NVO) Stock Holdings Reduced by Perigon Wealth Management LLC

Perigon Wealth Management LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,314 shares of the company’s stock after selling 3,318 shares during the period. Perigon Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,272,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NVO. International Assets Investment Management LLC raised its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $42,017,000. World Investment Advisors LLC boosted its holdings in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after purchasing an additional 270,234 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Novo Nordisk A/S by 71.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 475,490 shares of the company’s stock worth $57,413,000 after buying an additional 198,891 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.5 %

NVO opened at $85.33 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The business has a 50 day moving average of $94.32 and a 200-day moving average of $113.82. The stock has a market capitalization of $382.91 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Analyst Ratings Changes

NVO has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.